Risk of melanoma in people with HIV/AIDS in the preand post-HAART eras: A systematic review and meta- Analysis of cohort studies

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Olsen, Catherine M ^a   Knight, Lani L ^a   Green, Adèle C ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANCER RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; ETHNICITY; GENETIC HETEROGENEITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MELANOMA; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; BLACK PERSON; CAUCASIAN; COMPLICATION; DRUG EFFECTS; ETHNOLOGY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; META ANALYSIS; MIDDLE AGED; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; SKIN NEOPLASMS; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV-1; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; SKIN NEOPLASMS;

EID: 84899744971     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095096     Document Type: Article

References (50)

1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosup pressed transplant recipients: A meta-analysis. Lancet 370: 59-67. (Pubitemid 47017468)
2. Long JL, Engels EA, Moore RD, Gebo KA (2008) Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 22: 489-496. (Pubitemid 351317290)
3. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860. (Pubitemid 28135961)
4. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, et al. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403.
5. Flegg PJ (1990) Potential risks of ultraviolet radiation in HIV infection. Int J STD AIDS 1: 46-48. (Pubitemid 20204587)
6. Cebon J, Gedye C, John T, Davis ID (2007) Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 5: 994-1006. (Pubitemid 351479719)
7. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Metaanalysis of observational studies in epidemiology: A proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group, Jama 283: 2008-2012. (Pubitemid 30214957)
8. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 62: 1006-1012.
9. Wong WC, Cheung CS, Hart GJ (2008) Development of a quality assessment tool for systematic reviews of observational studies (QATSO) of HIV prevalence in men having sex with men and associated risk behaviours. Emerg Themes Epidemiol 5: 23.
10. Van den broucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, et al. (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147: 163-194.
11. World Health Organisation (W.H.O.) (2006) W.H.O. case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Switzerland.
12. Der Simonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
13. Hardy RJ, Thompson SG (1998) Detecting and describing heterogeneity in meta-analysis. Stat Med 17: 841-856. (Pubitemid 28185164)
14. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
15. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
16. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315: 629-634. (Pubitemid 27387172)
17. Vella S, Schwartlander B, Sow SP, Eholie SP, Murphy RL (2012) The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 26: 1231-1241.
18. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et al. (1996) Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 276: 146-154.
19. Moore RD (2011) Epidemiology of HIV infection in the United States: implications for linkage to care. Clin Infect Dis 52 Suppl 2: S208-S213.
20. Cress RD, Holly EA (1997) Incidence of cutaneous melanoma among non- Hispanic whites, Hispanics, Asians, and blacks: An analysis of california cancer registry data, 1988-93. Cancer Causes Control 8: 246-252. (Pubitemid 27170380)
21. Cooksley CD, Hwang LY, Waller DK, Ford CE (1999) HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data. Int J STD AIDS 10: 795-802.
22. Frisch M, Biggar RJ, Engels EA, Goedert JJ (2001) Association of cancer with AIDS-related immunosuppression in adults. JAMA 285: 1736-1745. (Pubitemid 32259908)
23. Gallagher B, Wang Z, Schymura MJ, Kahn A, Fordyce EJ (2001) Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 154: 544-556. (Pubitemid 32867954)
24. Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, et al. (2003) Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virusinfected patients. J Clin Oncol 21: 3447-3453. (Pubitemid 46594077)
25. Hessol NA, Seaberg EC, Preston-Martin S, Massad LS, Sacks HS, et al. (2004) Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr 36: 978-985. (Pubitemid 38949847)
26. Newnham A, Harris J, Evans HS, Evans BG, Moller H (2005) The risk of cancer in HIV-infected people in southeast England: A cohort study. Br J Cancer 92: 194-200. (Pubitemid 40188455)
27. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, et al. (2006) Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20: 1645-1654. (Pubitemid 44162407)
28. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, et al. (2007) The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 165: 1143-1153. (Pubitemid 47233717)
29. Serraino D, Piselli P, Busnach G, Burra P, Citterio F, et al. (2007) Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 43: 2117-2123. (Pubitemid 47381577)
30. Patel P, Hanson DL, SullivanPS, Novak RM, Moorman AC, et al. (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148: 728- 736. (Pubitemid 351717418)
31. Dal-Maso L, Polesel J, Serraino D, Lise M, Piselli P, et al. (2009) Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 100: 840-847.
32. van Leeuwen MT, Vajdic CM, Middleton MG, McDonald AM, Law M, et al. (2009) Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS 23: 2183-2190.
33. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, et al. (2009) Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27: 884-890.
34. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, et al. (2010) Changing patterns of cancer incidence in the early- And late-HAART periods: The Swiss HIV Cohort Study. Br J Cancer 103: 416-422.
35. Vogel M, Friedrich O, Luchters G, Holleczek B, Wasmuth JC, et al. (2011) Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence. Eur J Med Res 16: 101- 107.
36. Simard EP, Pfeiffer RM, Engels EA (2010) Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 170: 1337-1345.
37. Seaberg EC, Wiley D, Martinez-Maza O, Chmiel JS, Kingsley L, et al. (2010) Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 116: 5507-5516.
38. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, et al. (2011) HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 20: 2551-2559.
39. Calabresi A, Ferraresi A, Festa A, Scarcella C, Donato F, et al. (2013) Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy, 1999-2009. HIV Med.
40. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC (2009) Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 52: 203-208.
41. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, et al. (2008) Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123: 187-194. (Pubitemid 351705208)
42. Shiels MS, Cole SR, Kirk GD, Poole C (2009) A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52: 611-622.
43. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, et al. (2002) Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288: 222-235. (Pubitemid 34755283)
44. Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC (2012) HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 24: 506-516.
45. Houghton AN, Gold JS, Blachere NE (2001) Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 13: 134-140. (Pubitemid 32176030)
46. Kalialis LV, Drzewiecki KT, Klyver H (2009) Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 19: 275- 282.
47. Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, et al. (2001) Direct evidence to support the role of antigen-specific CD8(+) T cells in melanomaassociated vitiligo. J Invest Dermatol 117: 1464-1470. (Pubitemid 34032775)
48. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
49. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
50. Silverberg MJ, Leyden W, Warton EM, Quesenberry CP Jr., Engels EA, et al. (2013) HIV infection status, immunodeficiency, and the incidence of nonmelanoma skin cancer. J Natl Cancer Inst 105: 350-360.